Interesting stuff. The link below is to an article that includes a bit of additional information from a conference call held after the release Bromley posted.
http://yahoo.reuters.com/financeQuoteCo ... 376_newsml
The interesting bit for me is:
"On the call, Genzyme said the company and the FDA agree that Campath, which is currently approved to treat a form of leukemia, should not be used off-label."
Since most of the drugs used off-label for MS are immune-surpressing chemo drugs with significant side-effects, to recommend against off-label use of Campath says a lot about the dangers it potentially poses.